Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Les Laboratoires Servier, a European pharmaceutical company, has signed a $352m deal with Miragen Therapeutics for research and drug development concerning cardiovascular disease.
Subscribe to our email newsletter
The companies will lay emphasis on developing and commercializing three drug candidates, including two of Miragen’s programs (miR-208 and miR-15/195) and one additional target which is to be identified.
Miragen will receive up to $45m in total upfront, research support and near-term milestone payments over the next three years.
Additional clinical and commercial milestones for the development of the three compounds, would value the deal at around $1bn.
This agreement is said to provide worldwide rights to Servier, excluding the US and Japan.